<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "\\amrndhw017\ESMLogs\icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254114_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151549</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013028737</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>2</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130122</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013028737</companynumb>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Joseph</reportergivename>
			<reportermiddlename>R</reportermiddlename>
			<reporterfamilyname>Lamb</reporterfamilyname>
			<reporterstreet>1405 Mill Street</reporterstreet>
			<reportercity>New London</reportercity>
			<reporterstate>WI</reporterstate>
			<reporterpostcode>54961</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>84</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>Allergies to Antihistamines, Diphenhydramine - Type Benadryl; Ibuprofen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug allergy</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug hypersensitivity</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Dyspnea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dyspnea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>18-989</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>IBUPROFEN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug allergy</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug allergy</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>BENADRYL</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>DIPHENHYDRAMINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a non-clinical-study program Pfizer Helpful Answers. A contactable physician reported that an 84-year-old female patient of an unspecified ethnicity started to receive ibuprofen, via an unspecified route of administration on an unspecified date at an unspecified dose for an unspecified indication and diphenhydramine hydrochloride (BENADRYL), via an unspecified route of administration on an unspecified date at an unspecified dose for an unspecified indication. The patient's medical history and concomitant medications were not reported. The patient reported that "he was allergies to antihistamines, diphenhydramine - type benadryl; ibuprofen" (reported as of 15Jan2013) and experienced dyspnea on an unspecified date. The action taken in response to the events for ibuprofen and diphenhydramine hydrochloride was unknown. The outcome of the events was unknown.

Pfizer is Marketing Authorization Holder of ibuprofen in the reporter's country. This may be a duplicate report in situations where another Marketing Authorization Holder of ibuprofen has submitted the same report to the regulatory authorities.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
